Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP-1929 photoimmunotherapy vs physician’s choice chemotherapy in recurrent head and neck squamous cell carcinoma
jRCT2080224527Phase 3Completed
- Sponsor
- Rakuten Medical, Inc.
- Start
- Jan 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of cetuximab sarotalocan sodium in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Rakuten Medical, Inc. Started Jan 2019; status: completed.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080224527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224527.